Losmapimod Safety and Efficacy in COVID-19
Trial details
- Registry ID
- NCT04511819
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Losmapimod Safety and Efficacy in COVID-19NCT04511819 | Fulcrum Therapeutics | Phase 3 | Terminated | 2021-03-31Actual |
| Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)NCT04003974 | Fulcrum Therapeutics | Phase 2 | Completed | 2021-01-28Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |